In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals Ltd (ASLN), with a price target of $8.50. The company’s shares closed yesterday at $3.88.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.4% and a 36.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aslan Pharmaceuticals Ltd with a $8.50 average price target.
See today’s analyst top recommended stocks >>
Based on Aslan Pharmaceuticals Ltd’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $11.14 million. In comparison, last year the company had a GAAP net loss of $8.7 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002.
